The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19

Liam Rose¹, Laura Graham¹, Allison Koenecke², Michael Powell³, Ruoxuan Xiong⁴, Zhu Shen⁵, Kenneth W. Kinzler⁶, Chetan Bettegowda⁶,⁷, Bert Vogelstein⁶, Susan Athey⁸, Joshua T. Vogelstein³,⁹, Maximilian F. König⁶,¹⁰, Todd H. Wagner¹,¹¹*+

¹VA Health Economics Resource Center, Palo Alto VA, Menlo Park, CA, USA
²Institute for Computational & Mathematical Engineering, Stanford University, Stanford, CA, USA
³Department of Biomedical Engineering, Institute for Computational Medicine, The Johns Hopkins University, Baltimore, MD, USA
⁴Management Science & Engineering, Stanford University, Stanford, CA, USA
⁵Department of Statistics, Stanford University, Stanford, CA, USA
⁶Ludwig Center, Lustgarten Laboratory, and the Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA
⁷The Johns Hopkins University School of Medicine, Baltimore, MD, USA
⁸Stanford Graduate School of Business, Stanford University, Stanford, CA, USA
⁹Department of Biostatistics, The Johns Hopkins Bloomberg School of Public Health at The Johns Hopkins University, Baltimore, MD, USA
¹⁰Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, US
¹¹Department of Surgery, Stanford University, Stanford, CA, USA

* Correspondence:
Todd Wagner, VA Health Economics Resource Center, Palo Alto VA, Menlo Park, CA, USA, Department of Surgery, Stanford University, Stanford, CA, USA. Email: twagner@stanford.edu

+co-senior authors

Keywords: retrospective cohort study, COVID-19, SARS-CoV-2, hyperinflammation, alpha-1 adrenergic receptor antagonist, doxazosin, catecholamine, in-hospital mortality

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and preclinical data suggest alpha-1 adrenergic receptor antagonists (\(\alpha_1\)-AR antagonists) may be effective in reducing mortality related to hyperinflammation independent of etiology. Using a retrospective cohort design with patients in the Department of Veterans Affairs healthcare system, we use doubly robust regression and matching to estimate the association between baseline use of \(\alpha_1\)-AR antagonists and likelihood of death due to COVID-19 during hospitalization. Having an active prescription for any \(\alpha_1\)-AR antagonist (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) at the time of admission had a significant negative association with in-hospital mortality (relative risk reduction 18%; odds ratio 0.73; 95% CI 0.63 to 0.85; \(p \leq 0.001\)) and death within 28 days of admission (relative risk reduction 17%; odds ratio 0.74; 95% CI 0.65 to 0.84; \(p \leq 0.001\)). In a subset of patients on doxazosin specifically, an inhibitor of all three alpha-1 adrenergic receptors, we observed a relative risk reduction for death of 74% (odds ratio 0.23; 95% CI 0.03 to 0.94; \(p = 0.028\)) compared to matched controls not on any \(\alpha_1\)-AR antagonist at the time of admission. These findings suggest that use of \(\alpha_1\)-AR antagonists may reduce mortality in COVID-19, supporting the need for randomized, placebo-controlled clinical trials in patients with early symptomatic infection.
1 Introduction

The viral replication phase in Coronavirus disease 2019 (COVID-19) can be followed by a hyperinflammatory host immune response, hereafter referred to as COVID-19-associated hyperinflammation, which can lead to acute respiratory distress syndrome (ARDS), multiorgan dysfunction, and death despite maximal supportive care (1–4). While dexamethasone and other immunosuppressive strategies have shown some promise in improving outcomes in patients with severe COVID-19, they have not shown benefit (and may be detrimental) when given to patients with less advanced disease (5–7). To date, immunomodulatory therapeutic strategies that prevent the development of hyperinflammation and thereby halt progression to severe COVID-19 do not exist.

Catecholamines (adrenaline, noradrenaline, and dopamine) are monoamine hormones that signal through adrenergic receptors (ARs) expressed on tissues including cells of the immune system (8–10). Cells of the innate and adaptive immune system (phagocytes, lymphocytes) are capable of producing catecholamines de novo and signal in an autocrine/paracrine self-regulatory fashion (9,11). Beyond their well-established role in neurotransmission and physiological fight-or-flight responses, catecholamines have been shown to amplify immune responses and enhance acute inflammatory injury in vitro and in vivo by increasing cytokine production in immune cells (e.g., IL-6, TNF-α, MIP-2) (8,10–12). In animal models of hyperinflammation, prophylactic treatment with an alpha-1 adrenergic receptor (α1-AR) antagonist that inhibits all three receptor subtypes (α1A-, α1D-, and α1B-AR) can prevent cytokine storm and death by blocking deleterious catecholamine signaling and immune responses (11). In a retrospective analysis of patients hospitalized with acute respiratory distress, patients incidentally taking any α1-AR antagonist had a 34% relative risk reduction of being mechanically ventilated and dying (n=16,801, odds ratio 0.70) compared to non-users (13). Similarly, the risk of progression to mechanical ventilation and death was significantly reduced in a retrospective analysis of >300,000 patients hospitalized with pneumonia who were prescribed α1-AR antagonists prior to their index admission, suggesting that baseline inhibition of catecholamine signaling may improve clinical outcomes in acute lower respiratory tract infection or inflammation (13). We therefore hypothesized that early treatment with α1-AR antagonists can improve mortality and ameliorate disease in patients with symptomatic SARS-CoV-2 infection (14), but data demonstrating the efficacy of α1-AR antagonists in COVID-19 specifically is lacking.

The objective of this study was to examine the association of use of α1-AR antagonists with in-hospital mortality in patients with COVID-19. Here, we analyzed a large cohort of patients hospitalized at Veterans Health Administration (VA) hospitals, in whom α1-AR antagonists are commonly used to treat unrelated diseases such as benign prostatic hyperplasia (BPH), post-traumatic stress disorder (PTSD), or arterial hypertension (15). We hypothesized that patients with COVID-19 taking α1-AR antagonists at the time of hospital admission would be less likely to die during their hospitalization.

2 Methods

2.1 Study Population & Variables

We included all patients admitted to a VA hospital between February 20, 2020, and October 7, 2020 with a confirmed COVID-19 diagnosis (Figure 1). Diagnosis codes for COVID-19 were identified from the Centers for Disease Control and Prevention (CDC) coding guidelines for COVID-19 (16,17). The VA COVID-19 Shared Data Resource was used to identify VA patients with a SARS-CoV-2 laboratory test result (18). This data resource combines VA-specific lab results with non-VA lab results using text extraction from patient medical records. Because over 90% of α1-AR antagonist users in the analysis were older men, we excluded women to reduce unmeasured confounding unrelated
to COVID-19, specifically with respect to respiratory conditions. We also excluded patients under age 45 and patients over age 85 given the strong relationship between the severity of COVID-19 and age.

An expanded sample included all patients with laboratory-confirmed, “suspected positive”, or “possible positive” COVID-19 according to National COVID Cohort Collaborative (N3C) criteria (19). This Suspected COVID-19 sample excluded patients who tested negative for SARS-CoV-2. To the extent we can measure COVID-19 severity at time of admission, we find that this cohort was not operationally different from the main cohort based on vital signs at time of admission (Supplementary Figure 1).

The primary outcomes were death during the index hospitalization and death within 28 days of admission. The primary exposure variable was the use of α1-AR antagonists at the time of admission for the index hospitalization. Active prescriptions of α1-AR antagonists (tamsulosin, silodosin, prazosin, doxazosin, alfuzosin, and terazosin) were identified and defined by the patient having medication on hand on the day of the index admission, regardless of dosage. Secondary analyses examined the effect of tamsulosin (the most commonly prescribed α1-AR antagonist with selective antagonism on α1A- and α1D-, but not α1B-ARs) and doxazosin (a nonselective antagonist acting on all three α1-ARs) individually. Finally, with in-hospital therapies evolving during the pandemic, we repeated the analysis by week and VA hospital to ensure results were not driven by any particular time or location.

We obtained data on patient demographics, vital signs, and prescription drugs from the VA’s corporate data warehouse (CDW). Patient comorbidities were captured based on the International Classification of Diseases, Version 10 codes from VA care in the year prior to index admission. Other physiologic variables, including oxygen saturation and temperature, were defined at time of inpatient admission.

2.2 Analysis

Analyses followed the methodology of a companion paper examining patients with acute respiratory distress and pneumonia (13). Unadjusted analysis compared patients with α1-AR antagonist prescriptions to all other patients with COVID-19 using Fisher’s exact test. We then estimated propensity scores and trimmed the sample to ensure overlap in the propensity score distributions of the exposed and unexposed groups. On this reduced sample, the adjusted analysis used inverse propensity-weighted logistic regression adjusting for patient age at admission (input as a demeaned cubic polynomial to allow a nonlinear relationship), calendar week, location of hospitalization, and comorbidities diagnosed any time in the two years prior to the index inpatient stay. This approach is “doubly robust” in that it uses the observed confounders in both the calculation of the propensity score and the odds ratios. Comorbidities included in the matching procedure were diabetes mellitus, arterial hypertension, heart failure, ischemic heart disease, acute myocardial infarction, chronic obstructive pulmonary disease (COPD), end-stage renal disease (ESRD), and PTSD. We also included an indicator variable for oxygen saturation under 94 percent on the day of admission.

All of the control variables reflect information on patients prior to admission with COVID-19. As noted above, we controlled for secular changes in COVID-19 care using calendar week, starting with February 20, 2020. We chose not to examine endpoints during the hospital stay, such as use of a ventilator or admission to the ICU, given this is based on physician coding or data structures that we cannot assure were handled uniformly, especially during surges. We also chose not to control for processes of care during the stay given this could introduce bias in the analysis.
We then conducted a 5:1 matched analysis using the same covariates as the adjusted model (10). This approach assigns each exposed patient to a set of five unexposed patients most similar on observed characteristics and does not make assumptions about the functional form of the potential relationship between confounders and the outcome. Matches were selected using a greedy, nearest-neighbor approach based on Mahalanobis distance (11). The matched analysis used the Cochran-Mantel-Haenszel test to obtain odds ratios, confidence intervals, and p-values. We also present relative risk reductions (RRR) for the matched cohorts, and the pre- and post-matching balance of covariates is shown in Figure 3.

3 Results

3.1 Sample Characteristics

The sample contained 25,130 patients with COVID-19, with 5,600 patients taking any α₁-AR antagonist at time of admission. Of those taking α₁-AR antagonists, 73% of patients were on tamsulosin (n=4,078), 12% on terazosin (n=679), 10% on prazosin (n=581), 4% on doxazosin (n=215), 3% on alfuzosin (n=186), and less than 1% were on silodosin (n=5) (Figure 1). 177 patients had active prescriptions for more than one α₁-AR antagonist at the time of admission. Demographic characteristics, medical comorbidities, and Charlson Comorbidity Index for patient groups prior to matching is shown in Table 1. The differences in sample characteristics after matching are summarized in Figure 3. The top panel of Figure 2 shows the unadjusted, propensity score adjusted, and matched odds ratios among patients diagnosed with COVID-19 (n=25,130). The bottom panel expands the denominator to also include patients with suspected COVID-19 (n=32,016). The dark green odds ratios in Figure 2 represent all α₁-AR antagonists, while the lighter green represent doxazosin. Results were similar for the suspected COVID-19 sample. Patients taking any α₁-AR antagonists, compared to non-users, had an 20% relative risk reduction for death (p ≤ 0.001) in this cohort (Figure 2).

The use of doxazosin, a nonselective α₁-AR antagonist targeting all three α₁-AR subtypes, resulted in a 74% relative risk reduction for death in hospitalized patients with COVID-19 during the index admission (2/155=1.3% in matched treatment group vs. 39/775=5.0% in matched control group, odds ratio for death 0.23; p=0.028, Figure 2). Use of tamsulosin, the most commonly prescribed α₁-AR antagonist in this cohort with selectivity for α₁A- and α₁D-ARs, was associated with a 18% relative risk reduction for death during the inpatient stay (odds ratio for death 0.77; p=0.002, Supplementary Figure 2). Even though COVID-19 has affected different parts of the United States at different times, we found no evidence that these results were driven by any particular time period or location (Supplementary Figures 3 and 4).
4 Discussion

In this retrospective analysis of patients with COVID-19, we found a significant negative association between the use of α1-AR antagonists and in-hospital or 28-day mortality. These results are consistent with findings from a recent retrospective study of >300,000 patients hospitalized with pneumonia or ARDS unrelated to SARS-CoV-2 infection that identified a significant risk reduction for the progression to mechanical ventilation and death in individuals who were receiving any α1-AR antagonists as compared to non-users (5), suggesting that the benefits of α1-AR inhibition for mortality may be independent of etiology in patients with lower respiratory tract infection or inflammation.

Interestingly, we found much larger effect sizes in reducing mortality for patients treated with doxazosin, an antagonist on all three α1-AR subtypes (α1A-, α1D-, and α1B-AR), than for a pooled population of patients treated with any α1-AR antagonist in whom tamsulosin was the most common drug (72%). This was similarly true for patients treated exclusively with tamsulosin, a “uroselective” α1-AR antagonist on α1A- and α1D-ARs without clinically relevant inhibition of α1B-ARs expressed by immune cells and the peripheral vasculature (20). In patients with test-confirmed COVID-19, baseline use of doxazosin was associated with significantly reduced in-hospital and 28-day mortality compared to controls (odds ratio for death during admission 0.19 in adjusted cohort; odds ratio and relative risk reduction for death 0.23 and 74% in matched cohort, respectively). Baseline use of tamsulosin in patients with confirmed COVID-19, by comparison, was associated with significant, but less pronounced reductions in mortality. A similar trend was previously observed in patients with pneumonia in whom use of doxazosin was associated with lower risk of mechanical ventilation and death than tamsulosin (13). These observed differences in effect size are biologically plausible and may reflect the distinct pharmacological selectivity of doxazosin and tamsulosin for α1-AR subtypes.

Immune cells can induce expression of all three α1-AR subtypes (i.e., α1A-, α1D-, and α1B-ARs (21), and catecholamine signaling through these individual receptors may be highly redundant (12). As such, α1-AR antagonists acting on all three receptor subtypes (i.e., doxazosin, prazosin, alfuzosin, terazosin) may be required to effectively interrupt autocrine and paracrine catecholamine signaling in monocytes and other immune cells that enhance inflammatory injury (14,20). Indeed, preclinical data suggests that nonselective α1-AR antagonists are effective in preventing hyperinflammation and death in animal models of cytokine storm syndrome (11). The markedly improved survival in patients on doxazosin as compared to tamsulosin or any α1-AR antagonist (a cohort highly enriched in tamsulosin use) may therefore be consistent with a redundancy in catecholamine signaling pathways which are globally inhibited by doxazosin, whereas tamsulosin allows for continued signaling through the α1B-AR. These findings have practical implications for the selection of α1-AR antagonists for the prevention of inflammatory injury and suggest that the immunomodulatory benefits may not be uncoupled from inhibition of α1B-ARs expressed on the peripheral vasculature.

Additional studies have explored the efficacy of α1-AR blockade in the prevention of inflammatory and autoimmune injury. In a model of encephalitis, early α1-AR inhibition reversed neutrophil infiltration in lungs and prevented hemorrhagic pulmonary edema (22). The non-selective α1-AR antagonist prazosin has been shown to ameliorate experimental autoimmune encephalomyelitis (23). In a preclinical model of ischemia-reperfusion injury, prazosin administration resulted in decreased expression of IL-6, TNF-α, IL-10, and IL-1, and prevented mortality (24). Finally, α1-AR antagonism has been shown to block cytokine production in human peripheral blood mononuclear cells from patients with juvenile polyarticular arthritis, and treatment with doxazosin abrogated catecholamine-augmented secretion of IL-6 (25). These studies suggest a role of catecholamine-
associated augmentation of injurious cytokine responses beyond cytokine release syndrome and acute lung infection and highlights the potential of \( \alpha_1 \)-AR antagonists across various inflammatory diseases.

One concern with observational analysis is confounding by indication, especially if medications given during a hospital stay are correlated with disease severity. To avoid confounding by indication, this analysis examined the use of \( \alpha_1 \)-AR antagonists prior to index hospitalization. This class of medications is primarily used to manage chronic diseases such as arterial hypertension, PTSD, or BPH. As such, prescribing practices would not be biased by the severity of COVID-19. In addition, our results were not driven by a specific location or time period.

This study has important strengths and weaknesses. We have focused on mortality as a definitive clinical outcome, thereby avoiding process measures, such as use of mechanical ventilators or admission to an ICU, that are subject to local and individual practice patterns and would be biased if clinicians or hospitals changed their practices in unobserved ways. Another strength is our use of information prior to the COVID-19 admission for risk adjustment. One limitation in this study was the exclusion of women which was required due to limitations in samples size since \( \alpha_1 \)-AR antagonists are most commonly used to treat benign prostatic hyperplasia and 90% of patients in the VA system are men (26). A second limitation, best addressed in prospective clinical trials, was our inability to examine dose effects given our sample size.

Our results suggest that inhibition of catecholamine signaling with doxazosin (and other \( \alpha_1 \)-AR antagonists) may reduce in-hospital and 28-day mortality in patients with COVID-19 and highlight the need for randomized placebo-controlled clinical trials to examine the efficacy of \( \alpha_1 \)-AR antagonists for improving survival and preventing adverse outcomes from COVID-19. Importantly, \( \alpha_1 \)-AR antagonists are inexpensive, administered orally, do not require refrigeration, and have a well-established safety profile. Thus, if trials confirm these results, \( \alpha_1 \)-AR antagonists could be widely deployed to reduce mortality from inflammatory injury. Importantly, \( \alpha_1 \)-AR antagonists are immunomodulatory, but not immunosuppressive drugs. Long-term use of doxazosin does not appear to be associated with the development of opportunistic infection in human studies (27). Indeed, some studies suggest an overall decreased risk of urinary tract infection compared to placebo as may be expected based on its effect on dynamic prostate and bladder function (28). The absence of serious infectious complications may be explained by the unique mechanism of action of \( \alpha_1 \)-AR antagonists compared to immunosuppressive drugs currently employed in the treatment of severe COVID-19 (e.g., dexamethasone, baricitinib, tocilizumab) which confer an increased risk of opportunistic infection.

In summary, patients hospitalized with COVID-19 had lower odds of in-hospital and 28-day death if they had an active prescription for any \( \alpha_1 \)-AR antagonist (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) at the time of admission. Among different \( \alpha_1 \)-AR antagonists, doxazosin was associated with a 74% relative risk reduction for death, while tamsulosin had a more modest 18% relative risk reduction for death. A clinical trial testing the efficacy and safety of \( \alpha_1 \)-AR antagonists such as doxazosin to prevent hyperinflammation and reduce mortality in COVID-19 would appear warranted.

5 Conflict of Interest

In 2017, The Johns Hopkins University (JHU) filed a patent application on the use of various drugs to prevent cytokine release syndromes, on which BV and KWK are listed as inventors. JHU will not assert patent rights from this filing for treatment related to COVID-19. MFK received personal fees from Bristol-Myers Squibb and Celltrion, unrelated to the manuscript. BV and KWK are founders of and hold equity in Thrive Earlier Detection. KWK is a consultant to and is on the Board of Directors.
of Thrive Earlier Detection. BV and KWK are founders of, hold equity in, and serve as consultants to Personal Genome Diagnostics. KWK and BV are consultants to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. BV is also a consultant to Nexus. KWK and BV are consultants to and hold equity in NeoPhore. CB is a consultant to Depuy-Synthes and Bionaut Pharmaceuticals. CB, BV, and KWK are also inventors on technologies unrelated or indirectly related to the work described in this article. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict of interest policies. SA is an advisor and holds an equity stake in two private companies, Prealize (Palo Alto, California, USA) and Dr. Consulta (Brazil). Prealize is a healthcare analytics company, and Dr. Consulta operates a chain of low-cost medical clinics in Brazil.

6 Author Contributions

JV, BV, CB, and MK conceived of the presented idea. LR, LG, AK, MP, and RX conducted statistical analyses and results presentation. AK, MP, RX, ZS, and SA developed the methodology. LR, MK, JV, TW wrote the manuscript with input from all authors. All authors reviewed the final manuscript.

7 Funding

The work of Allison Koenecke is supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE – 1656518. Dr. Konig was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award no. T32AR048522. Dr. Bettegowda was supported by the Burroughs Wellcome Career Award for Medical Scientists. Dr. Athey was supported by the Office of Naval Research under Grant N00014-17-1-2131. This work was further supported by The Virginia and D.K. Ludwig Fund for Cancer Research, The Lustgarten Foundation for Pancreatic Cancer Research, the BKI Cancer Genetics and Genomics Research Program. Dr. Wagner was funded by a VA Research Career Scientist Award (RCS-17-154). Research, including data analysis, was partially supported by funding from Microsoft Research and Fast Grants, part of the Emergent Ventures Program at The Mercatus Center at George Mason University.

8 Acknowledgments

Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the US Department of Veterans Affairs or the National Science Foundation.

This project was sponsored by the VA Office of Reporting, Analytics, Performance, Improvement and Deployment, and the VA Center for Medication Safety, and approved as quality improvement by the Stanford University Institutional Review Board.
References

1. Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, Khan E, Mehta P, Martin-Gutierrez L, Waddington KE, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. *Lancet Rheumatol* (2020) 2:e594–e602. doi:10.1016/S2665-9913(20)30275-7

2. Faigenbaum DC, June CH. Cytokine Storm. *N Engl J Med* (2020) 383:2255–2273. doi:10.1056/NEJMra2026131

3. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O, et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. *Arthritis Rheumatol* (2020) 72:1059–1063. doi:10.1002/art.41285

4. Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A, Starr N, Buckel W, Grisel N, Hummel E, et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. *Lancet Rheumatol* (2020) 2:e754–e763. doi:10.1016/S2665-9913(20)30343-X

5. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med* (2020) doi:10.1056/NEJMo2021436

6. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med* (2021) 384:20–30. doi:10.1056/NEJMo2030340

7. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med* (2020) doi:10.1056/NEJMo2031994

8. Barnes MA, Carson MJ, Nair MG. Non-traditional cytokines: How catecholamines and adipokines influence macrophages in immunity, metabolism and the central nervous system. *Cytokine* (2015) 72:210–219. doi:10.1016/j.cyto.2015.01.008

9. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. *Nature* (2007) 449:721–725. doi:10.1038/nature06185

10. Grisanti LA, Perez DM, Porter JE. Modulation of immune cell function by α(1)-adrenergic receptor activation. *Curr Top Membr* (2011) 67:113–138. doi:10.1016/B978-0-12-384921-2.00006-9

11. Staedtke V, Bai R-Y, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. *Nature* (2018) 564:273–277.

12. Grisanti LA, Woster AP, Dahlman J, Sauter ER, Combs CK, Porter JE. α1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages. *J Pharmacol Exp Ther* (2011) 338:648–657. doi:10.1124/jpet.110.178012
13. Koenecke A, Powell M, Xiong R, Shen Z, Fischer N, Huq S, Khalafallah AM, Trevisan M, Sparen P, Carrero JJ, et al. Alpha-1 adrenergic receptor antagonists to prevent acute respiratory distress syndrome and death from cytokine storm syndrome. arXiv e-prints (2020) Available at: https://ui.adsabs.harvard.edu/abs/2020arXiv200410117K/abstract

14. König MF, Powell M, Staedtke V, Bai R-Y, Thomas DL, Fischer N, Huq S, Khalafallah AM, Koenecke A, Xiong R, et al. Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. J Clin Invest (2020) 130:3345–3347.

doi:10.1176/appi.ajp.2013.12081133

16. CDC. ICD-10-CM official coding guidance interim advice for coronavirus Feb 20, 2020.

17. CDC. ICD-10-CM official coding and reporting guidelines COVID-19 Guidelines April 1, 2020 through September 30, 2020.

18. Department of Veterans Affairs COVID-19 National Summary. Available at: https://www.accessstocare.va.gov/Healthcare/COVID19NationalSummary

19. National Center for Advancing Translational Sciences. National COVID Cohort Collaborative Phenotype Data Acquisition. Available at: https://github.com/National-COVID-Cohort-Collaborative/Phenotype_Data_Acquisition/wiki/Latest-Phenotype

20. Araki T, Monden K, Araki M. Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a short-term crossover study. Acta Med Okayama (2013) 67:245–251. doi:10.18926/AMO/51069

21. Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci (2010) 25:1–21.

22. Lu W-H, Hsieh K-S, Lu P-J, Wu Y-S, Ho W-Y, Cheng P-W, Lai C-C, Hsiao M, Tseng C-J. Different Impacts of α- and β-Blockers in Neurogenic Hypertension Produced by Brainstem Lesions in Rat. Anesthesiology (2014) 120:1192–1204. doi:10.1097/ALN.0000000000000218

23. Brosnan CF, Goldmuntz EA, Cammer W, Factor SM, Bloom BR, Norton WT. Prazosin, an alpha 1-adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat. Proc Natl Acad Sci U S A (1985) 82:5915–5919. doi:10.1073/pnas.82.17.5915

24. Wang L, Xue Y, Ma H, Shi H, Wang L, Cui X. Prazosin protects myocardial cells against anoxia-reoxygenation injury via the extracellular signal-regulated kinase signaling pathway. Mol Med Rep (2018) 17:2145–2152. doi:10.3892/mmr.2017.8175

25. Heijnen CJ, Rouppe van der Voort C, Wulffraat N, van der Net J, Kuis W, Kavelaars A. Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. J Neuroimmunol (1996) 71:223–226. doi:10.1016/s0165-5728(96)00125-7
26. US Department of Veterans Affairs, Veterans Health Administration. *The Changing Face of Women Veterans*. Available at: https://www.womenshealth.va.gov/WOMENSHEALTH/latestinformation/facts.asp

27. Drug Approval Package: Cardura XL (doxazosin mesylate) NDA #021269. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021269_carduraxl_toc.cfm [Accessed February 6, 2021]

28. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. *New England Journal of Medicine* (2003) 349:2387–2398. doi:10.1056/NEJMoa030656
|                          | Control (n = 19,316) | Any α1-AR antagonist (n = 5,600) | Overall (n = 25,130) |
|--------------------------|----------------------|----------------------------------|----------------------|
| **Age**                  |                      |                                  |                      |
| Mean (SD)                | 67.4 (9.02)          | 70.4 (7.83)                      | 68.1 (8.85)          |
| Median [Min, Max]        | 69.0 [45.0, 85.0]    | 72.0 [45.0, 85.0]                | 70.0 [45.0, 85.0]    |
| **Comorbidities in the prior year** |            |                                  |                      |
| Hypertension: n (%)      | 15603 (79.9%)        | 4955 (88.5%)                     | 20558 (81.8%)        |
| CAD: n (%)               | 776 (4.0%)           | 283 (5.1%)                       | 1059 (4.2%)          |
| CHF: n (%)               | 5611 (28.7%)         | 1866 (33.3%)                     | 7477 (29.7%)         |
| COPD: n (%)              | 6495 (33.2%)         | 2284 (40.8%)                     | 8779 (34.9%)         |
| Diabetes: n (%)          | 9695 (49.6%)         | 3076 (54.9%)                     | 12771 (50.8%)        |
| MI: n (%)                | 1347 (6.9%)          | 448 (8.0%)                       | 1795 (7.1%)          |
| BPH: n (%)               | 4989 (25.5%)         | 4412 (78.8%)                     | 9401 (37.4%)         |
| PTSD: n (%)              | 4199 (21.5%)         | 1661 (29.7%)                     | 5860 (23.3%)         |
| ESRD: n (%)              | 5902 (30.4%)         | 2063 (37.1%)                     | 7965 (31.9%)         |
| Charlson Comorbidity Index: mean (SD) | 4.00 (3.45) | 4.87 (3.53)                     | 4.47 (3.48)          |
| **VA Hospital**          |                      |                                  |                      |
| 508 (Atlanta, GA)        | 390 (2.0%)           | 113 (2.0%)                       | 503 (2.0%)           |
| 528 (VA Upstate New York, NY) | 346 (1.8%) | 100 (1.8%)                       | 446 (1.8%)           |
| 541 (Cleveland, OH)      | 335 (1.7%)           | 91 (1.6%)                        | 426 (1.7%)           |
| 549 (Dallas, TX)         | 393 (2.0%)           | 136 (2.4%)                       | 527 (2.1%)           |
| 573 (Gainesville, FL)    | 384 (2.0%)           | 134 (2.4%)                       | 518 (2.1%)           |
| 580 (Houston, TX)        | 525 (2.7%)           | 175 (3.1%)                       | 700 (2.8%)           |
| 589 (Kansas City, MO)    | 421 (2.2%)           | 171 (3.1%)                       | 592 (2.3%)           |
| 614 (Memphis, TN)        | 827 (4.2%)           | 264 (4.7%)                       | 1092 (4.3%)          |
| 626 (Nashville, TN)      | 471 (2.4%)           | 131 (2.4%)                       | 602 (2.4%)           |
| 630 (VA New York Harbor, NY) | 458 (2.3%) | 104 (1.9%)                       | 562 (2.2%)           |
| 636 (Omaha, NE)          | 286 (1.4%)           | 88 (1.6%)                        | 374 (1.5%)           |
| 644 (Phoenix, AZ)        | 413 (2.1%)           | 105 (1.9%)                       | 518 (2.1%)           |
| 657 (St Louis, MO)       | 388 (2.0%)           | 94 (1.7%)                        | 482 (1.9%)           |
| Location            | CAD (66.4%) | CHF (65.2%) | COPD (66.1%) |
|---------------------|-------------|-------------|--------------|
| 671 (San Antonio, TX) | 509 (2.6%)  | 119 (2.1%)  | 628 (2.5%)   |
| 673 (Tampa, FL)     | 413 (2.1%)  | 117 (2.1%)  | 530 (2.1%)   |
| Other VA hospitals  | 12973 (66.4%) | 3657 (65.2%) | 16630 (66.1%) |

CAD = coronary artery disease, CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, MI = acute myocardial infarction, BPH = benign prostatic hyperplasia, PTSD = post-traumatic stress disorder, ESRD = end-stage renal disease. PTSD was excluded from the adjusted analysis due to collinearity with other comorbidities. Listed VA hospitals had the most COVID-19 inpatient hospitalizations during the study period.
**Figure 1. CONSORT Flow Diagram**

1. COVID-19 inpatient stays, n = 60,795
2. Between 2/20/20 and 10/7/20, n = 34,792
3. Only men, n = 32,409
4. Women, n = 2,383
5. Between 45 and 85 years old, n = 27,440
6. Full Comorbidity Information, n = 25,130
7. Not on α1-AR antagonists, n = 19,530
   - Tamsulosin, n = 4,078
   - Terazosin, n = 679
   - Prazosin, n = 531
   - Doxazosin, n = 215
   - Alfuzosin, n = 186
   - Silodosin, n = 5
8. On α1-AR antagonists at time of admission, n = 5,600

Consort diagram. Note that the bottom row of medications are not mutually exclusive, with a small number of patients having more than one on hand at time of admission.
Figure 2: The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital and 28-Day Mortality from COVID-19

Department of Veterans Affairs: Mortality

**all α₁-AR antagonists | doxazosin**

**Diagnosed COVID-19 (n=25,130)**

| RRR   | OR     | (CI)    | p-value | n    |
|-------|--------|---------|---------|------|
| 0.84  | 0.74–0.95 | <0.001 | 25,130 |
| 0.85  | 0.73–0.97  | 0.018  | 25,130 |
| 0.74  | 0.65–0.84  | <0.001 | 23,276 |
| 0.74  | 0.64–0.86  | <0.001 | 23,276 |
| 17%   | 0.74      | 0.65–0.84 | <0.001 | 22,847|
| 18%   | 0.73      | 0.63–0.85 | <0.001 | 22,847|
| 0.44  | 0.18–0.94  | 0.030  | 19,742 |
| 0.34  | 0.09–0.89  | 0.020  | 19,742 |
| 0.38  | 0.17–0.86  | 0.020  | 10,610 |
| 0.19  | 0.06–0.60  | 0.004  | 10,610 |
| 54%   | 0.42      | 0.12–1.10 | 0.087  | 930   |
| 74%   | 0.23      | 0.03–0.94 | 0.028  | 930   |

**Suspected COVID-19 (n=32,016)**

| RRR   | OR     | (CI)    | p-value | n    |
|-------|--------|---------|---------|------|
| 0.84  | 0.76–0.93 | <0.001 | 32,016 |
| 0.83  | 0.73–0.93 | 0.001  | 32,016 |
| 0.72  | 0.65–0.80 | <0.001 | 29,924 |
| 0.71  | 0.63–0.81 | <0.001 | 29,924 |
| 18%   | 0.73      | 0.65–0.81 | <0.001 | 29,343|
| 20%   | 0.71      | 0.63–0.81 | <0.001 | 29,343|
| 0.55  | 0.29–0.95 | 0.028  | 24,920 |
| 0.54  | 0.24–1.05 | 0.070  | 24,920 |
| 0.39  | 0.21–0.73 | 0.003  | 14,833 |
| 0.31  | 0.15–0.65 | 0.002  | 14,833 |
| 52%   | 0.45      | 0.20–0.93 | 0.024  | 1,326 |
| 60%   | 0.38      | 0.12–0.97 | 0.040  | 1,326 |

Data are shown for hospitalized patients with confirmed COVID-19 (top panel) and with confirmed plus suspected COVID-19 (e.g., no confirmatory testing available, bottom panel). Forest plots show the odds ratios (OR) for in-hospital mortality based on prior use of any α₁-AR antagonists (i.e., tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin; dark green) or only doxazosin (light green) in each panel. Unadjusted (square), adjusted model (triangle), and matched model (circle) analyses are shown for each sample group. Filled symbols reflect the odds of death within 28 days from index hospital admission (including deaths after discharge), whereas empty symbols reflect odds of death during the index admission. Relative risk reduction (RRR), odds ratios (ORs) for death, 95% confidence intervals (CI), p-values, and sample size (n) for each analysis are shown on the right.
Figure 3. Standardized Mean Differences in Patient Characteristics Before and After Matching

The left panel shows the results for patients diagnosed with COVID-19. The right panel shows the results for patients diagnosed with COVID-19 plus suspected COVID-19 patients. Top panel show data for any α1-AR antagonists; bottom panel show data for doxazosin.
Supplementary Figure 1. Vital Signs at Time of Admission

The diagrams show vital signs for patients diagnosed with COVID-19 (red line) and an expanded cohort of patients with suspected COVID-19 (blue line). Smoothed lines are from a LOESS model with 95% confidence intervals shown (gray ribbons).

| Measure          | Diagnosed COVID-19 | Suspected COVID-19 | Difference |
|------------------|--------------------|--------------------|------------|
| O2 Sat <90%      | 0.038              | 0.046              | -0.007     |
| Average O2 Sat   | 95.816             | 95.672             | 0.144      |
| Average Temperature | 98.233          | 98.211             | 0.023      |
Supplementary Figure 2. In-hospital and 28-Day Mortality by Use of Tamsulosin at Time of Hospital Admission with COVID-19.

Department of Veterans Affairs: Mortality
all $\alpha_1$–AR antagonists | tamsulosin

**Diagnosed COVID-19 (n=25,130)**

| 28-day | unadjusted | adjusted | matched |
|--------|------------|----------|---------|
| in-hospital | □ unadjusted | △ adjusted | ● matched |

| RRR | OR (CI) | p-value | n |
|-----|---------|---------|---|
| 0.84 | (0.74–0.95) | 0.005 | 25,130 |
| 0.85 | (0.73–0.97) | 0.018 | 25,130 |
| 0.74 | (0.65–0.84) | <0.001 | 23,276 |
| 0.74 | (0.64–0.86) | <0.001 | 23,276 |
| 17% | 0.74 | (0.65–0.84) | <0.001 | 22,847 |
| 18% | 0.73 | (0.63–0.85) | <0.001 | 22,847 |
| 0.96 | (0.84–1.10) | 0.590 | 23,475 |
| 0.94 | (0.80–1.10) | 0.497 | 23,475 |
| 0.81 | (0.70–0.94) | 0.005 | 20,988 |
| 0.80 | (0.68–0.95) | 0.011 | 20,988 |
| 14% | 0.80 | (0.69–0.93) | 0.002 | 19,230 |
| 18% | 0.77 | (0.65–0.91) | 0.002 | 19,230 |

**Suspected COVID–19 (n=32,016)**

| 28-day | unadjusted | adjusted | matched |
|--------|------------|----------|---------|
| in-hospital | □ unadjusted | △ adjusted | ● matched |

| RRR | OR (CI) | p-value | n |
|-----|---------|---------|---|
| 0.84 | (0.76–0.93) | <0.001 | 32,016 |
| 0.83 | (0.73–0.93) | 0.001 | 32,016 |
| 0.72 | (0.65–0.80) | <0.001 | 29,924 |
| 0.71 | (0.63–0.81) | <0.001 | 29,924 |
| 18% | 0.73 | (0.65–0.81) | <0.001 | 29,343 |
| 20% | 0.71 | (0.63–0.81) | <0.001 | 29,343 |
| 0.94 | (0.84–1.05) | 0.283 | 29,875 |
| 0.90 | (0.78–1.02) | 0.104 | 29,875 |
| 0.77 | (0.69–0.87) | <0.001 | 27,120 |
| 0.74 | (0.64–0.85) | <0.001 | 27,120 |
| 16% | 0.79 | (0.70–0.88) | <0.001 | 24,956 |
| 21% | 0.73 | (0.63–0.84) | <0.001 | 24,956 |

Data are shown for hospitalized patients diagnosed with confirmed COVID-19 (top panel) and with confirmed plus suspected COVID-19 (bottom panel). Forest plots showing odds ratios (OR) of in-hospital mortality based on prior use of any alpha-1 adrenergic receptor antagonists (dark green) or tamsulosin (light blue) in each panel. Relative risk reduction (RRR), odds ratios (ORs) for death, 95% confidence intervals (CI), and p-values (for unadjusted, adjusted, and matched models), and sample size (n) for each analysis are shown on the right.
Supplementary Figure 3. Adjusted Odds of In-hospital Mortality and Use of \(\alpha_1\)-AR Antagonists by Week

Top panel shows adjusted odds ratios of in-hospital mortality and use of \(\alpha_1\)-AR antagonists by week of admission. Top panel truncated between 0 and 2 to aid visualization. Bottom panel shows number of new admissions by week and use of \(\alpha_1\)-AR antagonists (bottom).
Supplementary Figure 4. Adjusted Odds of In-hospital Mortality and Use of α₁-AR Antagonists by VA Station

Top panel shows adjusted odds ratios of in-hospital mortality in patients taking α₁-AR antagonists by VA station. Top panel truncated between 0 and 2 to aid visualization. Bottom panel shows number of new admissions and use of α₁-AR antagonists by VA station (bottom). For other VA stations, the number of admissions of patients not using α₁-AR antagonists was 7,645 and number of admissions of patients using α₁-AR antagonists was 1,845. VA stations shown: 508 = Atlanta, 549 = Dallas, 573 = Gainesville, 580 = Houston, 589 = Kansas City, 614 = Memphis, 630 = New York Harbor, 644 = Phoenix, 671 = San Antonio, 673 = Tampa.